OBJECTIVES: This randomized trial investigated to what extent loading with @entity3076 can provide a more rapid peri-interventional antiplatelet effect than @entity1397 600 mg. BACKGROUND: Effective platelet inhibition at the start of a percutaneous coronary intervention (PCI) reduces the risk of @entity63 complications. With @entity1397 administered immediately before a PCI, effective platelet inhibition is delayed by 2 h. @entity3076 has the potential of shortening this period. METHODS: We randomly assigned 300 @entity3075 receptor blocker-naive @entity1 undergoing an elective PCI to loading with @entity1397 600 mg, @entity3076 30 mg, or @entity3076 60 mg immediately before the PCI. Platelet function was assessed serially by impedance aggregometry. The primary endpoint was the proportion of @entity1 with high on-treatment platelet reactivity at 60 min after loading defined as  >= 468 aggregation units * minute (Multiplate Analyzer, Roche Diagnostics, Mannheim, Germany). RESULTS: The 3 groups were well balanced with respect to clinical and angiographic characteristics. At 60 min, 33% of the @entity1 assigned to @entity3076 60 mg, 37% of @entity1 assigned to @entity3076 30 mg, but 55% of those assigned to @entity1397 had high on-treatment platelet reactivity (p  < 0.001). At any time point starting from 30 min, @entity3076 60  mg achieved significantly lower platelet reactivity than @entity1397 . Platelet reactivity at 60 min after @entity3076 was not significantly different from that at 120 min after @entity1397 (p  = 0.18). @entity3076 30 mg had an intermediate effect. The 30-day incidence of @entity548 events was not different among the 3 groups. CONCLUSIONS: From 30 min onward, @entity3076 60 mg achieved a stronger platelet inhibition than @entity1397 loading in stable @entity1 undergoing a PCI. Compared with @entity1397 , @entity3076 60 mg was associated with a twice as fast onset of platelet inhibition. (Impact of Extent of @entity1397 -Induced Platelet Inhibition during Elective Stent Implantation on Clinical Event Rate-Advanced Loading Strategies [ExcelsiorLOAD]; DRKS00006102).

Randomized Comparison of Different  Thienopyridine Loading Strategies in XXXX Undergoing Elective  Coronary  Intervention: The ExcelsiorLOAD Trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3076 :: ('MESH:C408153', 'Chemical') :: ['prasugrel', 'Prasugrel'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['Clopidogrel', 'clopidogrel'] @entity3075 :: ('64805', 'Gene') :: ['P2Y12']
@entity1 :: (9606,Species) :: ['Patients']
